Literature DB >> 30186894

The differentially mitochondrial proteomic dataset in human ovarian cancer relative to control tissues.

Xianquan Zhan1,2,3,4, Tian Zhou1,2,3, Na Li1,2,3, Huanni Li5.   

Abstract

This data article presents a differentially mitochondrial proteomic dataset in human ovarian cancer tissues relative to control tissues. The mitochondrial samples were prepared from human ovarian cancer and control ovary tissues, and were digested with trypsin. The tryptic peptides from ovarian cancer and control mitochondrial samples were labeled by isobaric tags for relative and absolute quantification (iTRAQ) reagents, followed by strong-cation exchange (SCX) chromatography, liquid chromatography (LC)-tandem mass spectrometry (MS/MS), and bioinformatic analysis. This data article is related to a published article (Li et al., 2018) [1].

Entities:  

Year:  2018        PMID: 30186894      PMCID: PMC6123609          DOI: 10.1016/j.dib.2018.08.028

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Mitochondrial samples were digested with trypsin. The tryptic peptides were labeled with iTRAQ reagents. The iTRAQ labeled samples were mixed equally. The mixed iTRAQ samples were fractionated with SCX. Each fractionation was analyzed with LC-MS/MS. Database search and data analysis to determine each differentially expressed protein. Value of the data Mitochondria were separated and purified from ovarian cancer tissues and control ovary tissues, with high purity. Dataset includes 1198 differentially expressed proteins identified from ovarian cancer and control mitochondrial samples. Relative abundance (ratio of cancer to control), statistically significant p-value, peptide spectrum matches (PSMs), and database accession number might be useful for other researchers to select the method of choice according to the target of interests.

Data

Differentially expressed proteins (DEPs) identified between ovarian cancer and control mitochondrial samples are reported, with the corresponding PSMs, relative abundance (ratio of cancer to control), statistically significant p-value, and database accession number. Data are provided as supplementary file (Supplementary Table 1).

Experimental design, materials and methods

Sample preparation

Ovarian tissue samples, which include seven ovarian cancers and eleven control ovaries with benign gynecologic diseases, were collected from Department of Gynecology, Xiangya Hospital, which was approved by the Xiangya Hospital Medical Ethics Committee of Central South University, China. Mitochondria were prepared, their proteins were extracted, according to the protocols [1], [2], [3].

iTRAQ labeling and SCX-LC-MS/MS analysis

iTRAQ-labeling technology integrated with SCX-LC-MS/MS analysis [4], [5] were performed to identify DEPs in extracted mitochondrial protein samples from ovarian cancers and controls. In brief, mitochondrial proteins were digested with trypsin, and the tryptic peptides were labeled with the iTRAQ reagents according to the manufacturer׳s instructions (Applied Biosystems). The iTRAQ-labeled peptides were equally pooled and fractionated by SCX. Each collected fractionation was subjected to a 60-min LC-MS/MS analysis with a Q Exactive mass spectrometer (Thermo Scientific) equipped with Easy nLC (Proxeon Biosystems, now Thermo Fisher Scientific). MS/MS data were used to identify proteins with MASCOT engine (Matrix Science, London, UK; version 2.2) embedded into Proteome Discoverer 1.4. Mitochondrial DEPs were determined with the intensity difference of iTRAQ reporter ions [1].

Bioinformatic analysis

DAVID Bioinformatics Resources 6.7 (https://david.abcc.ncifcrf.gov/home.jsp) was used to analyze the mitochondrial DEPs, including biological process, cellular compartment, molecular function, and KEGG pathway enrichments [6].
Subject areaBiological medicine
More specific subject areaMitochondrial proteomics
Type of dataTable
How data was acquiredIsobaric tags for relative and absolute quantification (iTRAQ)-labeled samples were mixed and fractionated with strong-cation exchange (SCX) chromatography, followed by a 60-min liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis on a Q Exactive mass spectrometer (Thermo Scientific) that was coupled to Easy nLC (Proxeon Biosystems, now Thermo Fisher Scientific) for each fraction.
Data formatPDF file (Raw)
Experimental factorsMitochondria were separated and purified from human ovarian cancer tissues and control ovary tissues.
Experimental features

Mitochondrial samples were digested with trypsin.

The tryptic peptides were labeled with iTRAQ reagents.

The iTRAQ labeled samples were mixed equally.

The mixed iTRAQ samples were fractionated with SCX.

Each fractionation was analyzed with LC-MS/MS.

Database search and data analysis to determine each differentially expressed protein.

Data source locationXiangya Hospital, Central South University, Hunan 410008 PR China
Data accessibilityData is within this article, provided as supplementary file.
Related research articleN. Li, X.H. Zhan, X. Zhan. The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes. Gynecologic Oncology, 2018, 150 (2): 343–354. 10.1016/j.ygyno.2018.06.013[1]
  6 in total

1.  A high-throughput approach for subcellular proteome: identification of rat liver proteins using subcellular fractionation coupled with two-dimensional liquid chromatography tandem mass spectrometry and bioinformatic analysis.

Authors:  Xiao-Sheng Jiang; Hu Zhou; Lei Zhang; Quan-Hu Sheng; Su-Jun Li; Long Li; Pei Hao; Yi-Xue Li; Qi-Chang Xia; Jia-Rui Wu; Rong Zeng
Journal:  Mol Cell Proteomics       Date:  2004-01-22       Impact factor: 5.911

2.  Isolation of Peroxisomes from Mouse Brain Using a Continuous Nycodenz Gradient: A Comparison to the Isolation of Liver and Kidney Peroxisomes.

Authors:  Miriam J Schönenberger; Werner J Kovacs
Journal:  Methods Mol Biol       Date:  2017

3.  Proteomic analysis of solid pseudopapillary tumor of the pancreas reveals dysfunction of the endoplasmic reticulum protein processing pathway.

Authors:  Yi Zhu; Hong Xu; Hao Chen; Junjie Xie; Minmin Shi; Baiyong Shen; Xiaxing Deng; Chao Liu; Xi Zhan; Chenghong Peng
Journal:  Mol Cell Proteomics       Date:  2014-07-05       Impact factor: 5.911

4.  The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes.

Authors:  Na Li; Xiaohan Zhan; Xianquan Zhan
Journal:  Gynecol Oncol       Date:  2018-06-18       Impact factor: 5.482

5.  Proteomic and functional profiles of a follicle-stimulating hormone positive human nonfunctional pituitary adenoma.

Authors:  Xiaowei Wang; Tianyao Guo; Fang Peng; Ying Long; Yun Mu; Haiyan Yang; Ningrong Ye; Xuejun Li; Xianquan Zhan
Journal:  Electrophoresis       Date:  2015-06       Impact factor: 3.535

6.  iTRAQ-Based Proteomic Analysis reveals possible target-related proteins and signal networks in human osteoblasts overexpressing FGFR2.

Authors:  Tianyi Cai; Baojin Wu; Xinjie Tang; Zhaoping Zhou; Junyi Yang; Ronghu Ke; Xiongzheng Mu
Journal:  Proteome Sci       Date:  2018-06-19       Impact factor: 2.480

  6 in total
  1 in total

1.  Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics.

Authors:  Na Li; Xianquan Zhan
Journal:  EPMA J       Date:  2019-06-08       Impact factor: 6.543

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.